Google Answers Logo
View Question
 
Q: Human efficacy trials with experimental HIV Vaccine ( Answered,   0 Comments )
Question  
Subject: Human efficacy trials with experimental HIV Vaccine
Category: Health > Medicine
Asked by: geri1234-ga
List Price: $2.00
Posted: 28 Jan 2003 08:15 PST
Expires: 27 Feb 2003 08:15 PST
Question ID: 149522
I am looking for a company that is building a  production facility on
15,000 sqare feet of land south of San Francisco that is in
large-scale human efficacy trials with experimental HIV Vaccine
Answer  
Subject: Re: Human efficacy trials with experimental HIV Vaccine
Answered By: clouseau-ga on 28 Jan 2003 12:10 PST
 
Hello geri1234,

Thank you for your question. 

I searched ["experimental HIV Vaccine" +"san francisco"] to find the
following:

NATIONAL INSTITUTES OF HEALTH
http://www.nih.gov/news/pr/jan98/niaid-14.htm

"All six AVEG sites are participating in this study. Mary Lou
Clements-Mann, M.D., M.P.H., of Johns Hopkins University, is the study
chair. Both vaccines used in this study are manufactured by VaxGen of
South San Francisco, Calif."


Searching for vaxgen, I located this press release:

http://www.vaxgen.com/pressroom/index.html

"VaxGen Forms Joint Venture to Build Manufacturing Facilities In
California and South Korea; Facilities Designed to Support Potential
Regulatory Approval and Commercial Manufacture of VaxGen's AIDS
Vaccine

VaxGen, Inc. (Nasdaq: VXGN) and a group of South Korean investors
today announced the formation of a joint venture, which will invest
approximately $120 million to build and operate a facility in Incheon,
South Korea, to manufacture VaxGen's AIDS vaccine. The joint venture,
through the same $120 million investment, will also fund construction
of a smaller facility in South San Francisco, Calif., to support
licensure and commercial launch of the vaccine. Both facilities will
be used for commercial manufacture of the vaccine, AIDSVAX, if it
proves safe and effective and is licensed by the U.S. Food and Drug
Administration...

...In its first phase of development, the Incheon facility is expected
to be capable of producing up to 200 million doses of AIDSVAX per
year. The smaller facility in South San Francisco could produce up to
10 million doses of the AIDS vaccine per year and may also be used to
develop other pharmaceutical products. Celltrion expects to complete
construction of the smaller facility by the middle of 2003 and the
Incheon facility by the end of 2003. Additional time will be required
to validate and license each facility."

You will find contact information for VaxGen on their pages at
www.vaxgen.com .

I trust my research has located the information you desire. If a link
above should fail to work or anything require further explanation,
please do post a Request for Clarification and I will be pleased to
assist further.

Regards,

-=clouseau=-
Comments  
There are no comments at this time.

Important Disclaimer: Answers and comments provided on Google Answers are general information, and are not intended to substitute for informed professional medical, psychiatric, psychological, tax, legal, investment, accounting, or other professional advice. Google does not endorse, and expressly disclaims liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in answers or comments. Please read carefully the Google Answers Terms of Service.

If you feel that you have found inappropriate content, please let us know by emailing us at answers-support@google.com with the question ID listed above. Thank you.
Search Google Answers for
Google Answers  


Google Home - Answers FAQ - Terms of Service - Privacy Policy